This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Kaposiform haemangioendothelioma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

It is a rare, locally aggressive vascular tumour that is often associated with the Kasabach-Merritt syndrome.

Children and neonates are predominantly affected by this condition (1).

The tumour is usually solitary and occurs in the proximal arms and legs and the trunk (including the retroperitoneum). Craniofacial lesions are rare. Invasion of nearby organs is possible (1).

The lesion is characterised by rapid growth and variable shrinkage.

It doesn't regress spontaneously.

It manifests as a slightly raised subcutaneous mass and may appear purple and shiny with an advancing ecchymotic margin. Lesions are large in size (>5 cm in diameter). Tumours greater than 10 cm in diameter may be associated with thrombocytopaenia (1).

Kaposiform haemangioendotheliomas may be associated with lymphatic anomalies (2).

Kaposiform haemangioendothelioma should be differentiated from infantile haemangioma. Diagnosis is assisted by MRI (1).

Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon is associated with high mortality. Death may be caused by haemorrhage, sepsis, or invasion of vital structures (1).

Treatment options include corticosteroids, interferon alfa-2a, vincristine and cyclophosphamide. Excision, arterial embolization, and radiotherapy have all been used to treat the condition. Heparin is contraindicated (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.